Study of MYOCET in patients with HER2-Positive Breast Cancer

• Research type

  Research Study

• Full title

  Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast Cancer

• IRAS ID

  7521

• Contact name

  Stephen Chan

• Contact email

  steve.chan@nuh.nhs.uk

• Sponsor organisation

  Cephalon

• Eudract number

  2008-000709-12

• ISRCTN Number

  N/A

• Research summary

  Research Summary not published at request of researcher

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  08/H0604/168

• Date of REC Opinion

  20 Feb 2009

• REC opinion

  Further Information Favourable Opinion